Frontier Biotechnologies Inc. (688221.SS)
- Previous Close
5.83 - Open
5.94 - Bid 6.06 x --
- Ask 6.07 x --
- Day's Range
5.83 - 6.09 - 52 Week Range
5.09 - 13.16 - Volume
2,313,746 - Avg. Volume
4,266,997 - Market Cap (intraday)
2.274B - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-0.88 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health. The company's medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products in development include FB1002, an all-injectable long-acting HIV therapy; FB2001, a SARS-CoV-2 3CL protease inhibitor under clinical development for hospitalized patients as well as for post-exposure prophylaxis of Covid-19; FB3001, a new transdermal topical patch for musculoskeletal joint pain treatment under clinical development; and FB600, an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. The company was founded in 2013 and is headquartered in Nanjing, China.
www.frontierbiotech.comRelated News
Performance Overview: 688221.SS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688221.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688221.SS
Valuation Measures
Market Cap
2.18B
Enterprise Value
1.63B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.08
Price/Book (mrq)
1.63
Enterprise Value/Revenue
14.24
Enterprise Value/EBITDA
-5.91
Financial Highlights
Profitability and Income Statement
Profit Margin
-287.93%
Return on Assets (ttm)
--
Return on Equity (ttm)
-21.22%
Revenue (ttm)
114.25M
Net Income Avi to Common (ttm)
-328.96M
Diluted EPS (ttm)
-0.88
Balance Sheet and Cash Flow
Total Cash (mrq)
1.02B
Total Debt/Equity (mrq)
24.79%
Levered Free Cash Flow (ttm)
--
Research Analysis: 688221.SS
Company Insights: 688221.SS
688221.SS does not have Company Insights